

Figure S1. Serum (A) NID2 and (B) CDO1 methylation levels after propensity score matching analysis. *** $P < 0.001$. NID2, nidogen-2; CDO1, cysteine dioxygenase 1; NC, normal control; OC, ovarian cancer.






Figure S2. Diagnostic values of serum makers for patients with (A) FIGO stage I-II and (B) FIGO stage III-IV ovarian cancer. FIGO, International Federation of Gynecology and Obstetrics; NID2, nidogen-2; CDO1, cysteine dioxygenase 1; AUC, area under the curve.



— NID2 (AUC = 0.560; P = 0.491)
— CDO1 (AUC = 0.916; P < 0.001)
— CA125 (AUC = 0.893; P < 0.001)
— Reference line



— NID2 (AUC = 0.810; P < 0.001)
— CDO1 (AUC = 0.870; P < 0.001)
— CA125 (AUC = 0.878; P < 0.001)
— Reference line